anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
The invention relates to the treatment of musculoskeletal disorders, and more particularly to kinesiotherapeutic treatment methods. The claimed method includes taking a patient history and performing a functional assessment of the musculoskeletal system, whereupon the results are transmitted to a server, where a list of tentative diagnoses is generated, on the basis of which exercises are selected, with contraindicated exercises being excluding from the resulting list of exercises. The selected exercises are then transmitted to the patient in order to be performed in front of a mirror. A video sequence is then formed, in which the image of the patient is identified, and a 3D skeletal model is constructed in the form of an undirected graph, the vertices of which are located at reference points. Next, the angular displacement of each reference point is evaluated during execution of the prescribed exercises and compared with benchmark angular displacement values for said exercises. At the same time, the patient is informed of mistakes or is alerted if they should stop performing the exercises. The invention makes it possible to reduce the patient&#39;s risk of injury or of exacerbating a musculoskeletal disorder while performing kinesiotherapeutic exercises on their own, and also makes it possible to monitor the patient&#39;s progress and to check how regularly the exercises are performed.
PURPOSE:To provide an enteric drug having improved bioavailability, etc., by coating a drug with a mixture of an enteric polymer and a polyanionic polymer soluble under low pH condition. CONSTITUTION:An enteric drug can be prepared by coating a drug with a mixture of an enteric polymer (e.g. ethyl acrylate-methacrylic acid copolymer, vinyl acetate-crotonic acid copolymer, etc.) and a polyanionic polymer soluble under low pH condition (e.g. alginic acid, polypectinic acid, carboxymethylcellulose, etc.). In an environment of &lt;1-2 pH, the permeation of the liquid having the above pH in the drug or the release of the drug component into the liquid can be prevented, and on the contrary, the drug can be dissolved, dispersed or disintegrated in an environment having an arbitrary pH value higher than the above level. The molecular weight of the above polymeric substance and polymer is preferably the one corresponding to the viscosity of &lt;=500cps measured at 25 deg.C and 7.0pH as a 0.1% (W/W) aqueous solution with the B-type viscometer.
Werner&#39;s Syndrome helicase (WRN) interacts in Tat/TAR-RNA chromatin-remodeling complexes assembled on the HIV-1 LTR to promote transcriptional activation and viral replication. WRN markedly increases basal HIV-1 transcription and synergizes with Tat to support LTR trans-activation. Inhibition of WRN functions, through expression of the trans-dominant-negative WRN K577M  mutant, potently represses HIV-1 LTR trans-activation and prevents intracellular synthesis of p24 Gag  and inhibits virus production in HIV-infected H9 HIV-1IIIB  lymphocytes. Therefore, the present disclosure provides a novel target for anti-HIV therapy. Methods and compositions of the disclosure may be used to perform high throughput screens for small molecule anti-HIV therapeutics. Such therapeutics may inhibit a stage in the HIV replicative cycle not affected by current anti-HIV drugs.
The invention provides a traditional Chinese medicine preparation for externally treating cold-dampness arthralgia syndrome, relating to the field of Chinese medical treatment on traditional Chinese medicine arthralgia syndrome. The traditional Chinese medicine arthralgia syndrome belongs to current common diseases and frequently encountered diseases and is mainly characterized by pain, numbness, heaviness and unfavorable flexion and extension of muscles, bones and joints or even arthrocele and the like clinically. In the modern medicine, rheumatic arthritis, rheumatoid arthritis, gout, Raynaud&#39;s disease, ankylosing spondylitis, sciatica, osteoarthritis, hyperosteogeny and other degenerative changes belong to the field of arthralgia syndrome. The traditional Chinese medicine preparation for externally treating arthralgia syndrome has simple, convenient and easy paths, can avoid stimulation caused by alimentary tract administration, and can reduce toxic side effects of medicines. The traditional Chinese medicine prescription for externally treating cold-dampness arthralgia syndrome, which is provided by the invention, is prepared from american lopseed, clematis root, curcuma, argyi leaf, chuanxiong rhizome, safflower, mastic, myrrh, szechuan aconite and wild aconite, and has the functions of expelling wind and removing damness, activating blood circulation to dissipate blood stasis and eliminating cold to stop pain. The modern iontophoresis treatment technology is combined for treating arthralgia syndrome, thereby being favorable for the percutaneous absorption of the traditional Chinese medicine, increasing the effective utilization of the traditional Chinese medicine components, and acquiring a more satisfactory clinical treatment effect.
The invention discloses a reconstruction pill for treating hemiplegia and restoring consciousness, and a preparation method thereof. The traditional Chinese medicine composition comprises fineleaf schizonepeta herb, himalayan teasel roots, common four-o&#39;clock roots, Chinese honeylocust fruit, common jasminorange, pine nodular branches, stem of oriental bittersweet and radix glycyrrhizae. The traditional Chinese medicine composition can be prepared into any clinically-acceptable oral pharmaceutical preparation according to the conventional traditional Chinese medicine preparation method. The traditional Chinese medicine composition made of the traditional Chinese medicines has the efficacy of dredging collaterals and recovering hemiplegia, dispelling wind and resolving phlegm, tonifying kidney and reinforcing tendon, reinforcing qi and nourishing blood, and resolving hard lump. Clinical curative effect observation verifies that the traditional Chinese medicine composition disclosed by the invention can be used for comprehensively treating apoplexy hemiplegia symptoms such as hemiplegia, facial paralysis, numbness of limbs and the like, which are caused by apoplexy, and the curative effect is accurate, reliable and real. The traditional Chinese medicine composition is non-poisonous and harmless, safe and reliable, has no any side effect after being taken, and is safe in clinical use.
The present invention relates to a cosmetic composition for antioxidant effects and wrinkle reduction, comprising, as an active ingredient, extracts of one or more selected from the group consisting of Suaeda malacosperma H. Hara, Sedum oryzifolium Makino, Vicia angustifolia var. segetilis (Thuill.) K.Koch., Cerastium holosteoides var. hallaisanense (Nakai) Mizushima, and Fatsia japonica (Thunb.) Decne. &amp; Planch. The extracts provided in the present invention has excellent DPPH-scavenging activity and collagen forming effects, and thus may be used as cosmetic compositions for antioxidant effects and wrinkle reduction.
FIELD: veterinary immunology. SUBSTANCE: invention relates to methods of preparing specific sera against highly active biological substances. Method involves immunization of horse. For this purpose histoseroglobin with complete Freund&#39;s adjuvant is administrated in locus where surface cervical lymphatic nodes and lymphonodes of knee fold are located. Administration is carried out in both sites for two cycles at interval for 14 days between cycles. Then 8-9 l blood are taken away many times (two times, not less). At the first cycle a preparation is administrated twice: firstly by 5 ml of each substance and by 10 ml in 7 days. At the second stage - firstly by 10 ml and then - three times by 20, 40 and 80 ml at 4-5 days interval, respectively. EFFECT: high antibody titer of serum obtained, increased yield of ready product. 2 cl, 2 tbl, 2 ex
NEW MATERIAL:A monoclonal antibody NE-25, capable of carrying out antigen- antibody reaction with a protein antigen, present in human pulmonary parvicellular cancer and having 25X10&lt;3&gt; daltons molecular weight, having the following properties and belonging to IgG1 isotype. Reactive with human pulmonary parvicellular cancer, neuroglioma and neuroblastoma as well as normal cells of human nerve, thyroid gland and adrenal gland. Unreactive with normal tissues of human lungs, stomack, small intestines, colon and kidney. USE:A diagnostic agent for human pulmonary cancer. PREPARATION:For example, a cultivated strain of a pulmonary parvicellular cancer is administered to immunize a BALB/C mouse and splenic cells are collected and subjected to cell fusion with myelomatous cells to give a hybridoma, which is then cloned by a limiting dilution method, etc., and monocloned. The resultant hybridoma is further administered to a mouse abdominal cavity, etc., and multiplied to afford the aimed monoclonal antibody from the ascites.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a topically usable cosmetic agent or medicine, having a short absorbing time of a contained active ingredient, being absorbed in a large a proportion of the coated skin area, and facilitating the application.  &lt;P&gt;SOLUTION: The topically usable cosmetic agent or medicine includes the following components in a mixed state: a propellant containing a mixture of butane, propane and isobutane; hydrated alcohol-based gel; and at least one kind of topically used active ingredient. The mixed components are sprayed on the surface of the body to be treated from a pressurized container storing the mixed components. The propellant is vaporized from a liquid when coming out from the pressurized container and brought into contact with the surface of the body to be treated to form bubbles in the gel. The burst of the bubbles increases the kinetic energy of the gel accompanying the active ingredient, as a result, to heighten the absorbing rate into the layer of the skin.  &lt;P&gt;COPYRIGHT: (C)2007,JPO&amp;INPIT
PURPOSE:The titled inducer containing T lymphocytes obtained from warm- blooded animals damaged in the liver as an active ingredient. CONSTITUTION:A production inducer for cell growth factor, obtained by containing T lymphocytes, e.g. T lympocytes in body lymphatic tissues, e.g. the thymus, spleen, Bayer&#39;s lymphatic tissue, etc., obtained from warm-blooded animals, e.g. rat, mouse, chicken, goat, cattle, rabbit, pig, horse, etc., damaged in the liver as an active ingredient and usable as an injection. A buffer solution, glucose, etc., are added to T lymphocytes and used as a suspension. The above- mentioned inducer is injected into venous vascular systems or abdominal cavities of a normal warm-blooded animal and blood is collected after the lapse of a given time. Blood serum is obtained therefrom and purified to afford the aimed growth factor having a band at 6,000-48,000 molecular weight (according to an electropherogram with SDS polyacrylamide gel) without showing species specificity for animals.
507,376. Antipoliomyelitis serum. WESTERN RESERVE UNIVERSITY. May 26, 1938,&#39; No. 15795. Convention date, May 29, 1937. [Class 81 (i)] A serum effective against the virus of poliomyelitis is obtained by immunizing an animal by successive injections of poliomyelitis virus fortified with products of metabolism of intestinal bacteria and obtaining a serum from the blood of the animal. Material for fortifying the virus may for example comprise the endotoxins from strains of typhoid, paratyphoid and coli bacteria, together with the exotoxins from the growth of these strains in glucose broth. A solution of the virus in normal saline with which the fortifying material is to be admixed may be obtained by adsorbing the virus on aluminium hydroxide gel and eluting the adsorbed virus.
The hormone of the corpus luteum is concentrated by treating a solution containing the hormone in a solvent immiscible with water with one or more adsorbing agents and extracting the hormone from the adsorbent by means of an organic solvent.  Carbon disulphide, petroleum ether, benzene, toluene and ethyl acetate may be used as the solvent immiscible with water, suitable adsorbents are fuller&#39;s earth, alumina, fibrous alumina, kieselguhr, silica gel, kaolin, calcium carbonate, carbon.  For extracting the hormone from the adsorbent suitable solvents are ether, methyl or ethyl alcohol, acetone, chloroform or a mixture, e.g. of methyl alcohol and petroleum ether.  The extraction of the adsorbent is made at raised temperature.  After evaporation of the solvent the concentrated product is left in solid form or as a liquid which solidifies on standing.
PURPOSE:Rubber pressure-sensitive adhesive plaster obtained by blending plaster consisting of rubber pressure-sensitive adhesive with a caricaceous fruit and/or its emulsion, and protein, existing stably without causing decomposition of drug even after long-term preservation. CONSTITUTION:Rubber pressure-sensitive adhesive plaster obtained by blending plaster consisting of a rubber pressure-sensitive adhesive with a caricaceous fruit (unripe fruit of papaya) and/or its emulsion, and protein (e.g., albumin, gelatin, or keratin). Powder used is preferably obtained by drying emulsion oozed out from a cut end on an unripe fruit of papaya at low temperature &lt;=50 deg.C. It and protein are treated at 6-7pH at 30-40 deg.C for 1-2hr to give a filtrate, which is dried and used. The plaster is especially effective when a drug such as a phenolic hydroxyl group-containing compound, an amine compound, etc. having extreme reduction in content is pharmaceutically manufactured.
The invention relates to the use of a medicament with a mixture of substances and the use of a mixture of substances on the basis of active agents from the hypericum plant (St. John&#39;s wort) to produce a medicament. Extracts from St John&#39;s wort have long been used in medicine, but for a long time solely to treat psychogenic disorders and insomnia. Such extracts contain small quantities of polycyclic diones (hypericin, pseudohypericin and/or salts thereof). An anti-viral and especially anti-retroviral effect of hypericin and pseudohypercin in highly pure form has recently been observed. However, the administration of such preparations has considerable side-effects, making them useless for therapeutic use. According to the invention, the active agent hypericin is dispensed not in highly pure form, but mixed with known components of the plant extract. Here, the concentration of hypericin/pseudohypericin is between 0.05 and 50 %. This provides good antiretroviral action while largely avoiding the undesired side-effects.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide an item-management system, apparatus and method, which are preferably for management of items such as medicaments.  &lt;P&gt;SOLUTION: In several embodiments, the item-management system includes a holder defining a plurality of cells, a docking station configured to receive the holder, at least one indicator selectively-operable to indicate the holder cell into which an item is to be loaded, and at least one controller operable to selectively operate each at least one indicator to indicate the cell into which the item is to be received. In embodiments, indicators are provided on the holder. In other embodiments, the indicators may by on a guide associated with the docking station to assist the user in loading the holder. The contents of the loaded holder may be easily loaded, for example, into an automated dispensing machine for packaging and subsequent administration to a patient or for another use.  &lt;P&gt;COPYRIGHT: (C)2009,JPO&amp;INPIT
A method for identifying a molecule that restores Nod1 activity in cells which contain a Nod2 mutation that reduces or eliminates Nod1 activity. Nod2/CARD15 is the first characterized susceptibility gene in Crohn&#39;s disease. The Nod2 1007fs (Nod2fs) frameshift mutation is the most prevalent in Crohn&#39;s disease patients. Muramyl dipeptide (MDP) from bacterial peptidoglycan is the minimal motif detected by Nod2 but not by Nod2fs. The inventors investigated the response of human peripheral blood mononuclear cells (PBMCs) from Crohn&#39;s disease patients not only to MDP, but also to several other muramyl peptides. Unexpectedly, it was observed that patients homozygous for the Nod2fs mutation were totally unresponsive to MurNAc-L-Ala-D-Glu-mesoDAP (M-Tri DAP ), the specific agonist of Nod1. Accordingly, Gram-negative bacterial peptidoglycan, which can be detected by both Nod1 and Nod2, was unable to stimulate cytokine secretion from Nod2fs PBMCs. While M-Tri DAP  acts in synergy with both LTA and LPS to induce cytokine secretion from PBMCs of healthy donors, this phenomenon is attenutated in cells from Nod2fs patients.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide human antibody against respiratory syncytial virus that has at least one CDR (complementarity determining region) originated from at least one murine monoclonal antibody variable heavy chain CDR and at least one murine monoclonal antibody variable light chain, and is MAb1129, and to provide the use of the human antibody against respiratory syncytial virus for preventing and/or treating RSV (respiratory syncytial virus) infection.  &lt;P&gt;SOLUTION: A complementarity determining region (CDR)-grafted human antibody which contains at least one CDR from each variable heavy chain and variable light chain of at least one monoclonal antibody, against the RSV antigen. The monoclonal antibody may be derived from any non-human animal, preferably however, it is derived from a rodent and most preferably it is a murine monoclonal antibody. Preferably, the murine monoclonal antibody is a neutralizing antibody. It is also preferable that the murine antibody is an antibody against RSV F antigen.  &lt;P&gt;COPYRIGHT: (C)2009,JPO&amp;INPIT
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a method for manufacturing a pasting agent capable of suppressing an adhesive agent from being projected or flowed out from an end part.  &lt;P&gt;SOLUTION: In the manufacturing method for the pasting agent, an adhesion sheet provided with an adhesive agent layer on at least one surface of a support and a release liner on the adhesive agent layer is prepared. The manufacturing method includes a step for piercing the pasting agent provided with the adhesive agent layer on at least one surface of the support and the release liner on the adhesive agent layer from the adhesion sheet by a protrudent push cutter blade. Here, an angle a is larger than an angle b in a cross section shape perpendicular to an extension direction of the protrudent push cutter blade at at least a distal end part of the protrudent push cutter blade. Here, in the cross section shape, the angle a and the angle b have the meaning described in the present specification.  &lt;P&gt;COPYRIGHT: (C)2010,JPO&amp;INPIT
A method is disclosed for the treatment of hepadnavirus infection in animals. Animals infected with duck hepatitis B virus may be treated with the 2′,3′-dideoxynucleoside of adenine, guanine, hypoxanthine, 2,6-diaminopurine or various analogs of substituted purines. Several purine 2′,3′-­dideoxynucleosides inhibit duck hepatitis B virus in hepatocyte culture &gt;99% at 1 µg/ml. Potent  in vivo  efficacy of the 2,6-diaminopurine 2′,3′-­dideoxynucleoside for clearance of duck hepatitis B virus from the sera of Pekin ducks is demonstrated. The selective effect on hepadnavirus replication by the purine 2′,3′-dideoxynucleosides is based on the discovery of an unexpected sensitivity of hepadnavirus to purine 2′,3′-dideoxynucleoside analogs. These compounds present a new antiviral therapy of acute or persistent hepadnavirus infections.
PURPOSE:To obtain an aqueous preparation having excellent storage stability, capable of holding nitroglycerin at high concentration and causing little adsorption of nitroglycerin to an infusion set in drip infusion by dispersing nitroglycerin liposome in an aqueous solvent. CONSTITUTION:A nitroglycerin liposome is produced by using 1-50 pts.wt. (especially 3-10 pts.wt.) of lipid per 1 pt.wt. of nitroglycerin and using conventional method such as thin-film process, hydration process and freeze-drying process. The amount of the lipid is selected within the above range and to a level to effect the capture of &gt;=30% of the nitroglycerin to the lipid. The amount of nitroglycerin in the liposome-containing preparation is 0.01-25wt.%, preferably 0.1-15wt.% based on the total preparation.
The invention discloses a psoriasis treating pill, relating to an orally-taken traditional Chinese medicine pill for treating psoriasis. The pill is screened and developed in combination with the clinical experiences of more than 30 years of the inventor, and has the characteristics of short treatment period and low recurrence rate. The pathogenesis of the psoriasis generally lies in blood heat and air dryness leading to skin diseases and entering the blood system to cause irregularity between nutrient and defensive qi and blood as well as stasis after long time. The pill activates blood and resolves stasis, and discharges the lung fire in upper energizer, the stomach fire in middle energizer and the kidney fire in lower energizer; and the fire discharged from the three energizers goes out from the bladder. The pill also has the functions of clearing heat, cooling blood and dredging channels so that the channels move and the striae and all limbs and bones are dredged. Old saying goes &#39;blood is not treated if wind is treated only, and the wind is eliminated automatically when blood moves&#39; and &#39;heat is treated before wind, and the wind disappears when the heat is removed&#39;. The articles of blood and flesh are used for searching and eliminating wind evil and clearing dampness and heat. A large dose of bitter-cold medicine is used for clearing heat in blood. The psoriasis treating pill consists of 17 traditional Chinese medicines including rhizoma smilacis glabrae, fructus gardeniae, rhizoma coptidis, cortex phellodendri, radix scutellariae, buffalo horn, uniflower swisscentaury root, liquorice, Chinese angelica, rhizoma ligustici chuanxiong, naze, garter snake, periostracum cicada, tinea alba peel, poria cocos, radix paeoniae alba and radix paeoniae rubra. The medicines are suitable for the psoriasis pathogenesis that the wind cold dampness and heat lead to skin diseases and generate heat after long time and cause blood deficiency, air dryness and skin dystrophy.